This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Repligen Corp.

Drug Names(s): CTLA4-IgG4m

Description: RG2077 is a recombinant protein of CTLA4 (cytolytic-T-lymphocyte associated antigen-4) fused to the heavy chain constant region of the human immunoglobulin of the IgG4 isotype. The gene sequence encoding the immunoglobulin portion has been altered to remove the functional properties of binding the Fc receptor and fixation of complement.

CTLA4 is a key regulator of the normal activity of the immune system that turns off an immune response after it has successfully cleared an infection. Animal and human studies have suggested that a soluble form of CTLA4 (CTLA4-Ig) may be useful in treating autoimmune diseases and preventing organ transplant rejection.

RG2077 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug